Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 20 de 91
1.
Eur J Obstet Gynecol Reprod Biol ; 290: 27-37, 2023 Nov.
Article En | MEDLINE | ID: mdl-37716200

BACKGROUND: Following the publication of the European consensus statement on standards for essential colposcopy in 2020, the need for standards relating to more complex and challenging colposcopy practice was recognised. These standards relate to colposcopy undertaken in patients identified through cervical screening and tertiary referrals from colposcopists who undertake standard colposcopy only. This set of recommendations provides a review of the current literature and agreement on care for recognised complex cases. With good uptake of human papillomavirus (HPV) immunisation, we anticipate a marked reduction in cervical disease over the next decade. Still, the expert colposcopist will continue to be vital in managing complex cases, including previous cervical intraepithelial neoplasia (CIN)/complex screening histories and multi-zonal disease. AIMS: To provide expert guidance on complex colposcopy cases through published evidence and expert consensus. MATERIAL & METHODS: Members of the EFC and ESGO formed a working group to identify topics considered to be the remit of the expert rather than the standard colposcopy service. These were presented at the EFC satellite meeting, Helsinki 2021, for broader discussion and finalisation of the topics. RESULTS & DISCUSSION: The agreed standards included colposcopy in pregnancy and post-menopause, investigation and management of glandular abnormalities, persistent high-risk HPV+ with normal/low-grade cytology, colposcopy management of type 3 transformation zones (TZ), high-grade cytology and normal colposcopy, colposcopy adjuncts, follow-up after treatment with CIN next to TZ margins and follow-up after treatment with CIN with persistent HPV+, and more. These standards are under review to create a final paper of consensus standards for dissemination to all EFC and ESGO members.


Papillomavirus Infections , Uterine Cervical Dysplasia , Uterine Cervical Neoplasms , Female , Pregnancy , Humans , Colposcopy , Papillomavirus Infections/diagnosis , Early Detection of Cancer , Uterine Cervical Dysplasia/diagnosis , Papillomaviridae
2.
Int J Ment Health Nurs ; 32(6): 1515-1524, 2023 Dec.
Article En | MEDLINE | ID: mdl-37296514

Sleep quality and sleep duration are important for children's physical and mental health. Mental health diagnoses and sleep disturbances may be interlinked. We sought to identify the methods used to assess sleep in paediatric community-based mental health programmes. A systematic review was conducted using an a priori protocol to ascertain the sleep assessment methods used in paediatric community-based mental health programmes. Children for this review were defined as any person under the age of 19. Cochrane Library, CINAHL, Web of Science, ProQuest, APA PsycInfo, and PubMed databases were searched from January 2021 to March 2022. Of the 320 records screened, 314 records were excluded. Six studies were included for analysis. A variety of validated and non-validated sleep instruments were used to measure sleep quality and a range of sleep disturbances in community health programmes for children. There were a limited number of studies associated with sleep assessment in paediatric community-based settings suggesting this is an area of research that may be understudied. Sleep questionnaires were predominately completed by parents or guardians. Further research is required to establish the most effective method for screening sleep behaviour in paediatric community mental health programmes to understand the impact of sleep in the recovery of children and adolescents with mental health disorders.


Mental Disorders , Mental Health , Adolescent , Child , Humans , Mental Disorders/complications , Mental Disorders/diagnosis , Mental Disorders/therapy , Parents , Sleep , Public Health
4.
BJOG ; 128(5): 822-826, 2021 Apr.
Article En | MEDLINE | ID: mdl-32931650

There is increased awareness of transgender physical and mental health widely and in academic research. A significant proportion of transgender men will retain their cervix with an increased risk of cervical cancer. In this review of cervical cancer screening among transgender men, we try to estimate how many transgender men still have a cervix, understand to identify challenges and barriers to cervical screening and propose possible solutions. Organised cervical screening programmes need to consider the needs of this population, in particular the provision of HPV self-sampling. TWEETABLE ABSTRACT: Transgender men need access to cervical screening.


Early Detection of Cancer , Health Services for Transgender Persons , Transgender Persons , Uterine Cervical Neoplasms/prevention & control , Female , Humans , Male , Uterine Cervical Neoplasms/diagnosis
5.
Eur J Obstet Gynecol Reprod Biol ; 256: 57-62, 2021 Jan.
Article En | MEDLINE | ID: mdl-33171418

This European consensus statement on essential colposcopy provides standards for the general colposcopist seeing women referred for colposcopy with an abnormal cervical screening test (including cytology and HPV tests) or with a clinically suspicious cervix. The article gives guidance regarding the aims and conduct of colposcopy. Recommendations are provided on colposcopy technique, the management of common colposcopy issues, treatment and follow-up of after treatment of CIN or early stage cervical. Colposcopists should make an informed decision on the management of each individual that is referred and organize appropriate follow-up. Cervical cancer is still a major health issue and the quality of care can only improve if there is a structured guidance for women with an abnormal smear or suspicious cervix.


Papillomavirus Infections , Uterine Cervical Dysplasia , Uterine Cervical Neoplasms , Colposcopy , Consensus , Early Detection of Cancer , Female , Humans , Papillomaviridae , Papillomavirus Infections/diagnosis , Pregnancy , Uterine Cervical Neoplasms/diagnosis , Vaginal Smears , Uterine Cervical Dysplasia/diagnosis
6.
Contemp Nurse ; 56(4): 297-308, 2020 Aug.
Article En | MEDLINE | ID: mdl-32799620

Nurses and midwives of Australia now is the time for change! As powerfully placed, Indigenous and non-Indigenous nursing and midwifery professionals, together we can ensure an effective and robust Indigenous curriculum in our nursing and midwifery schools of education. Today, Australia finds itself in a shifting tide of social change, where the voices for better and safer health care ring out loud. Voices for justice, equity and equality reverberate across our cities, our streets, homes, and institutions of learning. It is a call for new songlines of reform. The need to embed meaningful Indigenous health curricula is stronger now than it ever was for Australian nursing and midwifery. It is essential that nursing and midwifery leadership continue to build an authentic collaborative environment for Indigenous curriculum development. Bipartisan alliance is imperative for all academic staff to be confident in their teaching and learning experiences with Indigenous health syllabus. This paper is a call out. Now is the time for Indigenous and non-Indigenous nurses and midwives to make a stand together, for justice and equity in our teaching, learning, and practice. Together we will dismantle systems, policy, and practices in health that oppress. The Black Lives Matter movement provides us with a 'now window' of accepted dialogue to build a better, culturally safe Australian nursing and midwifery workforce, ensuring that Black Lives Matter in all aspects of health care.


Administrative Personnel/psychology , Black or African American/psychology , Culturally Competent Care/organization & administration , Midwifery/education , Nursing Care/psychology , Nursing Staff, Hospital/psychology , Racism/prevention & control , Students, Nursing/psychology , Adult , Australia , Curriculum , Education, Nursing, Baccalaureate , Female , Humans , Leadership , Male , Middle Aged , Nursing Staff, Hospital/education , Pregnancy , Racism/psychology
7.
J Med Screen ; 25(2): 88-98, 2018 06.
Article En | MEDLINE | ID: mdl-28530513

Objectives To measure the feasibility and effectiveness of interventions to increase cervical screening uptake amongst young women. Methods A two-phase cluster randomized trial conducted in general practices in the NHS Cervical Screening Programme. In Phase 1, women in practices randomized to intervention due for their first invitation to cervical screening received a pre-invitation leaflet and, separately, access to online booking. In Phase 2, non-attenders at six months were randomized to one of: vaginal self-sample kits sent unrequested or offered; timed appointments; nurse navigator; or the choice between nurse navigator or self-sample kits. Primary outcome was uplift in intervention vs. control practices, at 3 and 12 months post invitation. Results Phase 1 randomized 20,879 women. Neither pre-invitation leaflet nor online booking increased screening uptake by three months (18.8% pre-invitation leaflet vs. 19.2% control and 17.8% online booking vs. 17.2% control). Uptake was higher amongst human papillomavirus vaccinees at three months (OR 2.07, 95% CI 1.69-2.53, p < 0.001). Phase 2 randomized 10,126 non-attenders, with 32-34 clusters for each intervention and 100 clusters as controls. Sending self-sample kits increased uptake at 12 months (OR 1.51, 95% CI 1.20-1.91, p = 0.001), as did timed appointments (OR 1.41, 95% CI 1.14-1.74, p = 0.001). The offer of a nurse navigator, a self-sample kits on request, and choice between timed appointments and nurse navigator were ineffective. Conclusions Amongst non-attenders, self-sample kits sent and timed appointments achieved an uplift in screening over the short term; longer term impact is less certain. Prior human papillomavirus vaccination was associated with increased screening uptake.


Early Detection of Cancer , Papillomavirus Infections/prevention & control , Patient Participation , Uterine Cervical Neoplasms/prevention & control , Vaginal Smears/statistics & numerical data , Adult , England , Female , Humans , Infant , Middle Aged , Papillomaviridae/immunology , Papillomavirus Infections/diagnosis , Papillomavirus Vaccines/administration & dosage , State Medicine , Treatment Outcome , Uterine Cervical Neoplasms/diagnosis , Young Adult
9.
BJOG ; 124(9): 1386-1393, 2017 Aug.
Article En | MEDLINE | ID: mdl-28102928

OBJECTIVE: To measure patterns of clinical activity at colposcopy before and after vaccinated women entered the Scottish Cervical Screening Programme (SCSP). DESIGN: Population-based observational study using nationally collected data. SETTING: Scottish colposcopy clinics. SAMPLE: All women with a date of birth on or after 1 January 1985 who attended colposcopy in Scotland between 2008 and 2014. METHODS: Routinely collected data from the Scottish National Colposcopy Clinical Information Audit System (NCCIAS) were extracted, including: referral criteria, referral cervical cytology, colposcopic findings, clinical procedures, and histology results. Analysis was restricted to those referred to colposcopy at age 20 or 21 years. MAIN OUTCOME MEASURES: Referral criteria, positive predictive value of colposcopy, default rates, and rates of cervical biopsies and treatments. RESULTS: A total of 7372 women referred for colposcopy at age 20 or 21 years were identified. There was a downward trend in the proportion of those referred with abnormal cytology (2008/9, 91.0%; 2013/14, 90.3%; linear trend P = 0.03). Women were less likely to have diagnostic or therapeutic interventions. The proportion with no biopsy (2008/9, 19.5%; 2013/14, 26.9%; linear trend P < 0.0001) and no treatment (2008/9, 74.9%; 2013/14, 91.8%; linear trend P < 0.0001) increased over the period of observation. CONCLUSIONS: A reduction in clinical activity related to abnormal screening referrals is likely to be associated with the human papillomavirus (HPV) catch-up immunisation programme. Referral criteria and the service provision of colposcopy needs to be planned carefully, taking account of the increasing number of women who have been immunised against HPV that will be entering cervical screening programmes worldwide. TWEETABLE ABSTRACT: Colposcopy referral criteria and service planning need attention following HPV immunisation programme.


Colposcopy/trends , Papillomavirus Infections/prevention & control , Papillomavirus Vaccines , Procedures and Techniques Utilization/trends , Uterine Cervical Dysplasia/diagnostic imaging , Uterine Cervical Neoplasms/diagnostic imaging , Workload/statistics & numerical data , Adult , Female , Humans , Logistic Models , Papillomavirus Infections/complications , Referral and Consultation/trends , Scotland , Sensitivity and Specificity , Uterine Cervical Neoplasms/pathology , Uterine Cervical Neoplasms/virology , Uterine Cervical Dysplasia/pathology , Uterine Cervical Dysplasia/virology
10.
BJOG ; 124(9): 1394-1401, 2017 Aug.
Article En | MEDLINE | ID: mdl-28102931

OBJECTIVE: To determine whether human papillomavirus (HPV) immunisation has affected the prevalence of HPV genotypes and colposcopic features of cervical intraepithelial neoplasia (CIN) in young women referred for colposcopy. DESIGN: A two-centre observational study including vaccinated and unvaccinated women. SETTING: Colposcopy clinics serving two health regions in Scotland, UK. POPULATION: A total of 361 women aged 20-25 years attending colposcopy following an abnormal cervical cytology result at routine cervical screening. METHODS: Cervical samples were obtained from women for HPV DNA genotyping and mRNA E6/E7 expression of HPV 16, 18, 31, 33, and 45. Demographic data, cytology, and histology results and colposcopic features were recorded. Chi-square analysis was conducted to identify associations between vaccine status, HPV genotypes, and colposcopic features. MAIN OUTCOME MEASURES: Colposcopic features, HPV genotypes, mRNA expression, and cervical histology. RESULTS: The prevalence of HPV 16 was significantly lower in the vaccinated group (8.6%) compared with the unvaccinated group (46.7%) (P = 0.001). The number of cases of CIN2+ was significantly lower in women who had been vaccinated (P = 0.006). The HPV vaccine did not have a statistically significant effect on commonly recognised colposcopic features, but there was a slight reduction in the positive predictive value (PPV) of colposcopy for CIN2+, from 74% (unvaccinated) to 66.7% (vaccinated). CONCLUSIONS: In this group of young women with abnormal cytology referred to colposcopy, HPV vaccination via a catch-up programme reduced the prevalence of CIN2+ and HPV 16 infection. The reduced PPV of colposcopy for the detection of CIN2+ in women who have been vaccinated is at the lower acceptable level of the UK national cervical screening programme guidelines. TWEETABLE ABSTRACT: Reduction of hrHPV positivity and CIN in immunised women consistent with lower PPV of colposcopy for CIN2+.


Colposcopy , Papillomaviridae/genetics , Papillomavirus Infections/virology , Papillomavirus Vaccines , Uterine Cervical Dysplasia/diagnostic imaging , Uterine Cervical Neoplasms/diagnostic imaging , Adult , Cross-Sectional Studies , Female , Genotype , Humans , Papillomaviridae/isolation & purification , Papillomavirus Infections/complications , Papillomavirus Infections/diagnosis , Papillomavirus Infections/prevention & control , Scotland , Uterine Cervical Neoplasms/pathology , Uterine Cervical Neoplasms/prevention & control , Uterine Cervical Neoplasms/virology , Uterine Cervical Dysplasia/pathology , Uterine Cervical Dysplasia/prevention & control , Uterine Cervical Dysplasia/virology
11.
Eur J Gynaecol Oncol ; 38(2): 196-198, 2017.
Article En | MEDLINE | ID: mdl-29953779

OBJECTIVE: To determine short-term complications and related risk factors following needle excision of the transformation zone (NETZ). MATERIALS AND METHODS: A case series of 105 women with NETZ for cervical pathology between 2006-2013 in a single center. RESULTS: The overall complication rate was 22.9%. Heavy primary bleeding occurred in 12.4% of cases (<500 ml), secondary hemorrhage 7.6%, emergency hysterectomy 1.9%, and cervical stenosis 2.9%. Where excision depth was > 20 mm, this was a non-significant increase in the risk of hemorrhage, but a significant reduction in the risk of a subsequent hysterectomy (p = 0.035). CONCLUSION: NETZ is associated with a number of complications and recognition of risk factors should be considered when planning type 3 excisional procedures and counseling women.


Blood Loss, Surgical , Gynecologic Surgical Procedures/adverse effects , Gynecologic Surgical Procedures/methods , Postoperative Hemorrhage/etiology , Uterine Cervical Dysplasia/surgery , Uterine Cervical Neoplasms/surgery , Adult , Blood Volume , Female , Gynecologic Surgical Procedures/instrumentation , Humans , Hysterectomy , Middle Aged , Needles , Neoplasm, Residual , Postoperative Hemorrhage/therapy , Reoperation , Retrospective Studies , Uterine Cervical Neoplasms/pathology , Young Adult , Uterine Cervical Dysplasia/pathology
12.
Psychooncology ; 26(4): 476-483, 2017 04.
Article En | MEDLINE | ID: mdl-27297097

OBJECTIVE: To compare psychosocial outcomes (follow-up related worries and satisfaction with follow-up related information and support) over 30 months of two alternative management policies for women with low-grade abnormal cervical cytology. METHODS: Women aged 20-59 years with low-grade cytological abnormalities detected in the National Health Service Cervical Screening Programme were randomised to cytological surveillance or initial colposcopy. A total of 3399 women who completed psychosocial questionnaires at recruitment were invited to complete questionnaires at 12, 18, 24 and 30 months. Linear mixed models were used to investigate differences between arms in the two psychosocial outcomes. Each outcome had a maximum score of 100, and higher scores represented higher psychosocial morbidity. RESULTS: On average, over 30 months, women randomised to colposcopy scored 2.5 points (95%CI -3.6 to -1.3) lower for follow-up related worries than women randomised to cytological surveillance. Women in the colposcopy arm also scored significantly lower for follow-up related satisfaction with information and support (-2.4; -3.3 to -1.4) over 30 months. For both outcomes, the average difference between arms was greatest at 12th- and 18th-month time points. These differences remained when the analysis was stratified by post-school education. CONCLUSIONS: Women with low-grade cytology, irrespective of their management, have substantial initial psychosocial morbidity that reduces over time. Implementation of newer screening strategies, which include surveillance, such as primary HPV screening, need to consider the information and support provided to women. © 2016 The Authors. Psycho-Oncology published by John Wiley & Sons Ltd.


Anxiety/psychology , Colposcopy/psychology , Cytodiagnosis/psychology , Uterine Cervical Dysplasia/psychology , Uterine Cervical Neoplasms/psychology , Adult , Female , Humans , Longitudinal Studies , Middle Aged , Morbidity , Surveys and Questionnaires , Uterine Cervical Neoplasms/pathology , Young Adult , Uterine Cervical Dysplasia/pathology
13.
Leukemia ; 31(1): 40-50, 2017 01.
Article En | MEDLINE | ID: mdl-27443263

To address the poor prognosis of mixed lineage leukemia (MLL)-rearranged infant acute lymphoblastic leukemia (iALL), we generated a panel of cell lines from primary patient samples and investigated cytotoxic responses to contemporary and novel Food and Drug Administration-approved chemotherapeutics. To characterize representation of primary disease within cell lines, molecular features were compared using RNA-sequencing and cytogenetics. High-throughput screening revealed variable efficacy of currently used drugs, however identified consistent efficacy of three novel drug classes: proteasome inhibitors, histone deacetylase inhibitors and cyclin-dependent kinase inhibitors. Gene expression of drug targets was highly reproducible comparing iALL cell lines to matched primary specimens. Histone deacetylase inhibitors, including romidepsin (ROM), enhanced the activity of a key component of iALL therapy, cytarabine (ARAC) in vitro and combined administration of ROM and ARAC to xenografted mice further reduced leukemia burden. Molecular studies showed that ROM reduces expression of cytidine deaminase, an enzyme involved in ARAC deactivation, and enhances the DNA damage-response to ARAC. In conclusion, we present a valuable resource for drug discovery, including the first systematic analysis of transcriptome reproducibility in vitro, and have identified ROM as a promising therapeutic for MLL-rearranged iALL.


Depsipeptides/pharmacology , Myeloid-Lymphoid Leukemia Protein/genetics , Precursor Cell Lymphoblastic Leukemia-Lymphoma/pathology , Animals , Antibiotics, Antineoplastic/pharmacology , Cell Line, Tumor/drug effects , Cyclin-Dependent Kinases/antagonists & inhibitors , Gene Rearrangement , Heterografts , Histone Deacetylase Inhibitors/pharmacology , Humans , Infant, Newborn , Mice , Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy , Proteasome Inhibitors/pharmacology
14.
Br J Cancer ; 114(5): 582-9, 2016 Mar 01.
Article En | MEDLINE | ID: mdl-26931370

BACKGROUND: To document the effect of bivalent HPV immunisation on cervical cytology as a screening test and assess the implications of any change, using a retrospective analysis of routinely collected data from the Scottish Cervical Screening Programme (SCSP). METHODS: Data were extracted from the Scottish Cervical Call Recall System (SCCRS), the Scottish Population Register and the Scottish Index of Multiple Deprivation. A total of 95 876 cytology records with 2226 linked histology records from women born between 1 January 1988 and 30 September 1993 were assessed. Women born in or after 1990 were eligible for the national catch-up programme of HPV immunisation. The performance of cervical cytology as a screening test was evaluated using the key performance indicators used routinely in the English and Scottish Cervical Screening Programmes (NHSCSP and SCSP), and related to vaccination status. RESULTS: Significant reductions in positive predictive value (16%) and abnormal predictive value (63%) for CIN2+ and the mean colposcopy score (18%) were observed. A significant increase (38%) in the number of women who had to be referred to colposcopy to detect one case of CIN2+ was shown. The negative predictive value of negative- or low-grade cytology for CIN2+ increased significantly (12%). Sensitivity and specificity, as used by the UK cervical screening programmes, were maintained. CONCLUSIONS: The lower incidence of disease in vaccinated women alters the key performance indicators of cervical cytology used to monitor the quality of the screening programme. These findings have implications for screening, colposcopy referral criteria, colposcopy practice and histology reporting.


Papillomavirus Infections/prevention & control , Papillomavirus Vaccines/therapeutic use , Squamous Intraepithelial Lesions of the Cervix/pathology , Uterine Cervical Dysplasia/pathology , Uterine Cervical Neoplasms/pathology , Cohort Studies , Colposcopy , Cytodiagnosis , Early Detection of Cancer , Female , Humans , Papanicolaou Test , Predictive Value of Tests , Retrospective Studies , Scotland , Sensitivity and Specificity , Squamous Intraepithelial Lesions of the Cervix/diagnosis , Squamous Intraepithelial Lesions of the Cervix/prevention & control , United Kingdom , Uterine Cervical Neoplasms/diagnosis , Uterine Cervical Neoplasms/prevention & control , Vaginal Smears , Young Adult , Uterine Cervical Dysplasia/diagnosis , Uterine Cervical Dysplasia/prevention & control
15.
Br J Cancer ; 114(5): 576-81, 2016 Mar 01.
Article En | MEDLINE | ID: mdl-26794278

BACKGROUND: To measure the uptake of first invitation to cervical screening by vaccine status in a population-based cohort offered HPV immunisation in a national catch-up campaign. METHODS: A retrospective observational study of routinely collected data from the Scottish Cervical Screening Programme. Data were extracted and linked from the Scottish Cervical Call Recall System, the Scottish Population Register and the Scottish Index of Multiple Deprivation. Records from 201 023 women born between 1 January 1988 and 30 September 1993 were assessed. Women born in or after 1990 were eligible for the national catch-up programme of HPV immunisation. Attendance for screening was within 12 months of the first invitation at age 20 years. RESULTS: There was a significant decline in overall attendance from the 1988 cohort to the 1993 cohort with the adjusted attendance ratio of the 1988 cohort being 1.49 times (95% CI 1.46-1.52) that of the 1993 cohort. Immunisation compensated for this decrease in uptake with unvaccinated individuals having a reduced ratio of attendance compared with those fully vaccinated (RR=0.65, 95% CI 0.64-0.65). Not taking up the opportunity for HPV immunisation was associated with an attendance for screening below the trend line for all women before the availability of HPV immunisation. CONCLUSIONS: HPV immunisation is not associated with the reduced attendance for screening that had been feared. Immunised women in the catch-up cohorts appear to be more motivated to attend than unimmunised women, but this may be a result of a greater awareness of health issues. These results, while reassuring, may not be reproduced in routinely immunised women. Continued monitoring of attendance for the first smear and subsequent routine smears is needed.


Early Detection of Cancer/statistics & numerical data , Papillomavirus Infections/prevention & control , Papillomavirus Vaccines/therapeutic use , Uterine Cervical Neoplasms/prevention & control , Case-Control Studies , Female , Humans , Retrospective Studies , Scotland , Uterine Cervical Neoplasms/diagnosis , Young Adult
17.
Cytopathology ; 26(3): 178-87, 2015 Jun.
Article En | MEDLINE | ID: mdl-25099940

OBJECTIVE: Worldwide, each year, large numbers of women are referred for colposcopy following low-grade abnormal cervical cytology. Many have no visible abnormality on examination. The risk of cervical intra-epithelial neoplasia grade 2/3 (CIN2/3) in these women is low. It is unknown whether, for women, a normal colposcopy resolves the anxiety which often follows the receipt of an abnormal cytology result. We investigated the prevalence of adverse psychological outcomes over 30 months following a normal colposcopy. METHODS: This cohort study was nested within the UK TOMBOLA randomized controlled trial. Women aged 20-59 years, with recent low-grade cytology, who had a satisfactory colposcopy examination and normal transformation zone, completed the Hospital Anxiety and Depression Scale (HADS) and Process Outcome Specific Measure (POSM) at recruitment and during follow-up (12, 18, 24 and 30 months post-recruitment). Outcomes included percentages reporting significant anxiety (HADS anxiety subscale score ≥11), significant depression (HADS depression subscale score ≥8) or worries about the result of the next cytology test, cervical cancer, having sex, future fertility and general health at each time point (point prevalence) and during follow-up (cumulative prevalence). RESULTS: The study included 727 women. All psychological measures (except depression) had high prevalence at recruitment, falling substantially by 12 months. During follow-up, the cumulative prevalence of significant anxiety was 27% and significant depression was 21%. The most frequently reported worry was that the next cytology test would be abnormal (cumulative prevalence of 71%; point prevalence of ≥50% at 12 and 18 months). The cumulative prevalence values of worries about cervical cancer, having sex and future fertility were 33%, 20% and 16%, respectively. CONCLUSIONS: For some women who have low-grade cytology, a normal colposcopy does not appear to provide psychological reassurance.


Colposcopy/psychology , Early Detection of Cancer/psychology , Uterine Cervical Dysplasia/psychology , Adult , Cohort Studies , Early Detection of Cancer/methods , Female , Humans , Middle Aged , Uterine Neoplasms/diagnosis , Young Adult
18.
BJOG ; 122(3): 380-6, 2015 Feb.
Article En | MEDLINE | ID: mdl-24947656

OBJECTIVES: To determine the rate of cervical intraepithelial neoplasia grade 2 (CIN2+) in women with low grade cervical cytology and a normal colposcopy examination over 3 years of follow-up. DESIGN: Cohort study within a randomised controlled trial. SETTING: NHS Cervical Screening Programmes in Grampian, Tayside and Nottingham. POPULATION: Eight hundred and eighty-four women aged 20-59 years with borderline nuclear abnormalities (BNA) or mild dyskaryosis with a normal and adequate colposcopy examination. METHODS: Samples at baseline were tested for 14 high-risk (Hr) types using GP5+6+ methodology and for HPV 16 and 18 using type-specific primers. Women were followed up post-colposcopy by cervical cytology at 6-month intervals in primary care. After 3 years, women were invited for an exit colposcopy examination and underwent LLETZ if any colposcopic abnormality was identified. MAIN OUTCOME MEASURES: Absolute and relative risks of CIN2+ during follow-up and/or at exit colposcopy. RESULTS: The median age was 36 years. The absolute risk of developing CIN2+ within 3 years was 1.86 per 100 woman years and for CIN3+, 0.64 per 100 woman years. One microinvasive cancer was identified. The relative risk (RR) was highest for women with initial mild dyskaryosis who were HrHPV-positive (RR 5.86, 95% confidence interval 2.53-13.56) compared with women with BNA who were HrHPV-negative. CONCLUSION: For women with low grade cervical cytology, the risk of a high grade CIN within 3 years of a normal colposcopy examination is low. Women can be reassured that, even with a positive HPV test, the risk of developing CIN2 or worse is sufficiently low to return to the routine 3-year recall.


Cervix Uteri/pathology , Colposcopy , Uterine Cervical Dysplasia/pathology , Uterine Cervical Neoplasms/pathology , Adult , Anxiety , Cohort Studies , Colposcopy/psychology , Female , Follow-Up Studies , Humans , Mass Screening , Middle Aged , Quality Assurance, Health Care , Referral and Consultation/organization & administration , United Kingdom , Uterine Cervical Dysplasia/psychology , Vaginal Smears
19.
Br J Cancer ; 111(9): 1824-30, 2014 Oct 28.
Article En | MEDLINE | ID: mdl-25180766

BACKGROUND: In Scotland, a national HPV immunisation programme began in 2008 for 12- to 13-year olds, with a catch-up campaign from 2008 to 2011 for those under the age of 18. To monitor the impact of HPV immunisation on cervical disease at the population level, a programme of national surveillance was established. METHODS: We analysed colposcopy data from a cohort of women born between 1988 and 1992 who entered the Scottish Cervical Screening Programme (SCSP) and were aged 20-21 in 2008-2012. RESULTS: By linking datasets from the SCSP and colposcopy services, we observed a significant reduction in diagnoses of cervical intraepithelial neoplasia 1 (CIN 1; RR 0.71, 95% CI 0.58 to 0.87; P=0.0008), CIN 2 (RR 0.5, 95% CI 0.4 to 0.63; P<0.0001) and CIN 3 (RR 0.45, 95% CI 0.35 to 0.58; P<0.0001) for women who received three doses of vaccine compared with unvaccinated women. CONCLUSIONS: To our knowledge, this is one of the first studies to show a reduction of low- and high-grade CIN associated with high uptake of the HPV bivalent vaccine at the population level. These data are very encouraging for countries that have achieved high HPV vaccine uptake.


Papillomavirus Infections/prevention & control , Papillomavirus Vaccines/therapeutic use , Uterine Cervical Dysplasia/prevention & control , Uterine Cervical Neoplasms/prevention & control , Adult , Cohort Studies , Colposcopy , Female , Follow-Up Studies , Humans , Mass Screening , National Health Programs , Neoplasm Grading , Papillomaviridae/isolation & purification , Papillomavirus Infections/epidemiology , Papillomavirus Infections/pathology , Papillomavirus Infections/virology , Prevalence , Prognosis , Scotland/epidemiology , Uterine Cervical Dysplasia/epidemiology , Uterine Cervical Dysplasia/pathology , Uterine Cervical Dysplasia/virology , Uterine Cervical Neoplasms/epidemiology , Uterine Cervical Neoplasms/pathology , Uterine Cervical Neoplasms/virology , Vaccination , Vaccine Potency , Vaginal Smears , Young Adult
...